Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG Avacopan
Study Locations (20)
California
- Medvin Clinical Research — Covina
- Palo Alto Medical Foundation Fremont — Fremont
- The Nephrology Group — Fresno
- Providence Medical Foundation — Fullerton
- Medvin Clinical Research — Menifee
- University of California San Francisco- Zuckerburg San Francisco General — San Francisco
- Harbor University of California at Los Angeles Medical Center — Torrance
Florida
- Florida Kidney Physicians — Boca Raton
- Malcom Randall Veterans Affairs Medical Center — Gainesville
- Mayo Clinic — Jacksonville
- ClinTrial Research Oakwater, Llc — Orlando
- University of South Florida — Tampa
Arizona
- Scottsdale Healthcare at Shea - HonorHealth — Scottsdale
- Southwest Kidney Institute — Surprise
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
- Dunes Clinical Research LLC — Sioux City
Alaska
- Orthopedic Physicians Alaska — Anchorage
Colorado
- University of Colorado — Aurora
Georgia
- Emory University — Atlanta
Indiana
- Lake Cumberland Rheumatology — New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2036-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072482
The ClinicalTrials.gov registry entry for NCT06072482 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 266 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Antineutrophil Cytoplasmic Antibody-associated Vasculitis appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06072482 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06072482 about?
NCT06072482 is a clinical study titled "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis". The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
What is the current status of trial NCT06072482?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2024-02-07. Estimated completion is 2036-12-31.
What conditions does trial NCT06072482 study?
This clinical trial studies the following conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06072482?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), Avacopan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06072482?
This trial is sponsored by Amgen, which has 266 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06072482 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.